AACR II: Flat Dosing of Nivolumab in Patients Previously Treated for NSCLC
Posted: Thursday, July 2, 2020
A flat dose of nivolumab given over a 30-minute period appeared to be well tolerated with clinical activity in a cohort of predominantly Chinese patients with previously treated non–small cell lung cancer (NSCLC). These findings, based on a subgroup of patients from CheckMate 870, were presented by Shun Lu, MD, PhD, of Shanghai Chest Hospital, China, and colleagues during the American Association for Cancer Research (AACR) Virtual Annual Meeting II (Abstract CT218).
This phase IIIb trial recruited 400 patients with stage IIIB/IV NSCLC who had received no more than two prior therapies. Patients were administered an infusion of 240 mg of nivolumab over 30 minutes every 2 weeks until disease progression, unacceptable toxicity, or a maximum of 2 years. There were 34 patients in the cohort with mutations in EGFR as well as 17 with hepatitis B infections.
At the data cutoff in May 2019, the median duration of treatment was 3 months. The median progression-free survival was 3.7 months among all patients, with an objective response rate of 16%. On subgroup analysis, those with hepatitis B infection had a median progression-free survival of 2.0 months, with an 18% objective response rate, compared with 3.7 months and 15% in noninfected patients. Those with mutations in EGFR had a mean progression-free survival of 1.9 months, compared with 3.6 months in those without the mutation. Patients with squamous histology had a longer median progression-free survival than those with nonsquamous histology, 4.7 and 3.4 months, respectively. The median overall survival among all patients was not yet reached.
Grade 3 or 4 adverse events were reported in 13% of all patients, and 2% of patients discontinued therapy as a result. The most common grade 3 or 4 treatment-related adverse events included hepatotoxicity, skin toxicity, pulmonary and endocrine toxicities.
Disclosure: For a full list of authors’ disclosures, visit abstractsonline.com.
